中基健康(000972) - 2024 Q3 - 季度业绩预告

Financial Performance - The company expects a net loss attributable to shareholders between 35 million to 50 million yuan, representing a decline of 216.25% to 181.37% compared to the same period last year, where it reported a profit of 43.01 million yuan[2]. - Revenue is projected to be between 260 million to 330 million yuan, a decrease of 24.21% to 3.81% from the previous year's revenue of 343.06 million yuan[2]. - The company anticipates a net profit after deducting non-recurring gains and losses to also be between 35 million to 50 million yuan, reflecting a decline of 218.58% to 183.01% compared to last year's profit of 42.17 million yuan[2]. - Basic earnings per share are expected to be a loss of 0.0648 yuan to 0.0454 yuan, compared to earnings of 0.0558 yuan per share in the same period last year[2]. Market Challenges - The decline in performance is attributed to the shipping crisis affecting tomato processing companies, leading to reduced sales prices and volumes of the company's main product, bulk tomato sauce[5]. Strategic Initiatives - The company is actively developing flagship products in the fast-moving consumer goods and health products sectors, focusing on increasing domestic sales and improving marketing channels[5]. Financial Data Integrity - The preliminary financial data provided in the earnings forecast has not been audited by the accounting firm, and there are no significant discrepancies reported between the company and the auditors[4]. - The company has communicated with the accounting firm regarding the earnings forecast, ensuring alignment on the reported figures[3]. - The company emphasizes the importance of cautious decision-making for investors due to the preliminary nature of the financial data[6]. Earnings Forecast Period - The earnings forecast period covers January 1, 2024, to September 30, 2024[2].